Efficacy of ranibizumab combined with dexamethasone intravitreal implant in patients with branch retinal vein occlusion and macular edema
MAIDINA Nabijiang
MAIERHABA Yusufu
WEI Bi-xia
DING Lin
Abstract：Objective To investigate the effects of ranibizumab combined with dexamethasone intravitreal implant on vascular endothelial growth factors(VEGFs),interleukins(ILs),and clinical efficacy in patients with branch retinal vein occlusion and macular edema(BRVO-ME).Methods Seventy-four patients(74 eyes)diagnosed with BRVO-ME at the Department of Ophthalmology,People's Hospital of Xinjiang Uygur Autonomous Region,from June 2021 to June 2023 were selected for this study.The patients were randomly divided into the monoclonal treatment group(n=37)and the combination treatment group(n=37).The monoclonal treatment group received ranibizumab and saline intravitreal injections,while the combination treatment group received ranibizumab combined with dexamethasone intravit-real implant injections.Ophthalmologic indices[intraocular pressure(IOP),central macular thickness(CMT)],best-corrected visual acuity(BCVA),anterior chamber VEGFs(VEGF-A,VEGF-B),anterior chamber ILs(IL-6,IL-8)levels,and adverse events were compared before treatment and at 3 and 6 months after treatment.Results At 3 and 6 months post-treatment,the combination treatment group showed significantly lower mean CMT,BCVA,VEGF-A,IL-6,and IL-8 levels compared to before treatment and the monoclonal treatment group(P＜0.05).There were no statistically significant differences in IOP and VEGF-B levels between the groups(P＞0.05).The incidence of adverse events did not differ significantly between the two groups(P＞0.05).Conclusion Compared to ranibizumab alone,the combination of dexamethasone intravitreal implant with ranibizumab significantly improves visual quality and reduces in-flammatory cytokine levels in aqueous humor in patients with BRVO-ME.
Keywords：branch retinal vein occlusion with macular edemaranibizumabdexamethasone intravitreal implantvascular endothelial growth factorinterleukin
Publication Date：2024-11-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 1429-1433 )